Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
Huvudupphovsmän: | Bekker, P, Velde, A, Pronk, I, Keshav, S, Hommes, D, Hanauer, S, Ungashe, S, Zheng, W, Wright, K, Schall, T |
---|---|
Materialtyp: | Conference item |
Publicerad: |
2007
|
Liknande verk
Liknande verk
-
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
av: Keshav, S, et al.
Publicerad: (2007) -
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
av: Bekker, P, et al.
Publicerad: (2009) -
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
av: Keshav, S, et al.
Publicerad: (2009) -
PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
av: Keshav, S, et al.
Publicerad: (2007) -
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
av: Bekker, P, et al.
Publicerad: (2008)